

Open label randomised trial. Early combined treatment vs conventional.

Early combination (antiTNF+antimetabolite) with possibility of dose intensification of antiTNF. Conventional therapy was standard treatment at discretion of physician.

Primary outcome: Mean proportion of steroid free remission month 12.

Secondary outcomes: Proportion in remission and differences in mean HBI scores at months 6,18 and 24; time to occurrence of major adverse outcome (surgery or hospital admission)

Results:

12m: remission rates no differences between groups
24 month follow-up major adverse outcomes (surgery, hospitalization, disease complication) more freq in conventional 35.1% vs 27.7% ECI; $p=0.0003$

Conclusion:

Lower risk of major adverse outcomes in early combined immunosuppression in CD vs conventional treatment. However, no differences in remission rates at 12 months.




Figure 4: Proportion of patients in symptomatic remission over 24 months

